Growing clinical and research interest in Lp(a) as an independent risk factor for a spectrum of cardiovascular diseases was reflected in a broad range of presentations focused on Lp(a) at ACC.24 Scientific Sessions (6-8 April 2024, Atlanta, USA and online). These included fresh insights into the role of Lp(a) in patients with coronary artery disease or heart failure, the importance of Lp(a) measurement alongside other lipid tests, and the impact of Lp(a) testing on prescribing of and adherence to lipid lowering therapies. Presenters also addressed issues related to Lp(a) assays and considered the potential of Lp(a) as a factor in high risk populations for cardiovascular disease, such as those with HIV and those who develop cardiac allograph vasculopathy after heart transplantation.
Read the reports:
- Real world data support link between Lp(a) and CV events
- Impact of Lp(a) testing on lipid management
- Lp(a) measurement analysis supports less isoform-sensitive assay
- Lp(a) clue to impaired coronary endothelial function in HIV
- Does Lp(a) play a role in heart transplant morbidity and mortality?
Reporting by Jenny Bryan
